Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · X4 Pharmaceuticals, Inc (XFOR)

X4 Pharmaceuticals posts investor day presentation; Phase 3 topline data due Q1 2028

Neutral Impact 2 of 5 other Written later

X4 Pharmaceuticals filed an investor day presentation as Exhibit 99.1 to an 8-K and said it will post the deck on its website for its Investor Day event. The presentation updates the timeline for mavorixafor in primary chronic neutropenia, including full enrollment of the 4WARD Phase 3 study by the end of Q4 2026 and topline data in Q1 2028, with potential US FDA approval in late 2028 or early 2029.

Key points

  • The 8-K text refers to an October 29, 2029 Investor Day, while the exhibit is dated October 29, 2026.
  • 4WARD Phase 3 trial expects full enrollment of 126 patients by end of Q4 2026 and topline data in Q1 2028.
  • Potential US FDA approval for primary chronic neutropenia is expected in late 2028 or early 2029.
  • Phase 2b 4STEPS G-CSF dose reduction study is planned to start in Q1 2027, with topline data in H1 2028.

The filing

CompanyX4 Pharmaceuticals, Inc (XFOR)
Form8-K, current report
Filed with the SECOct 29, 2026, 9:59 AM ET
Accession number0001501697-26-000084

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 29, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.